^
Association details:
| Biomarker: | MET D1010N |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
Excerpt:
...our clinical case with concurrent MET p.D1010_splice mutation and PIK3CA-p.Glu542Lys had a significant and prolonged response to crizotinib...In summary, our results confirm that the multitargeted MET/ALK/ROS1 TKI crizotinib induces anti-tumor activity in lung adenocarcinomas driven by clinically-relevant MET amplification or MET exon 14 skipping mutation (even in the presence of co-occurring PIK3CA mutation)...
DOI:
10.1016/j.lungcan.2015.10.028
